Carbon Trade eXchange (CTX) Launches ITMO Carbon Auction: Investors Can Now Enter Most Important Carbon Market on Earth
3.7.2024 20:47:00 EEST | Business Wire | Press release
The long awaited ITMO Auction is ready to take buyer Registration via the world´s first and leading global Voluntary Carbon platform, Carbon Trade Exchange (CTX). Carbon market brokers, investors plus new players like family offices or funds can participate.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240703957790/en/
Malawi Vice President Honorable Michael Usi with Gold Standard CEO Margaret Kim at COP28 Dubai (Photo: Business Wire)
The Auction will commence on Tuesday 16thJuly to finish on Tuesday 23rd July2024, hosted at https://ctxglobal.com/auctions/. Auction starting price is $10 USD per credit, with minimum starting bid of only $250,000.
Featuring 1.5 million issued credits forsale, already escrowed in CTX’s Gold Standard Registry account, triggers much needed climate finance, benefiting people across Malawi. ITMO prices are forecast by many exerts to be $100+ by 2030.
The Dual Certified project (Gold Standard and UNFCCC CDM) has Malawi Government Letter of Authorisation under Article 6 - Malawi support this Auction. “We want the carbon market to boost the country’s economy, create jobs and real benefits in our towns and villages and so we look forward to a successful auction and hope this can be the first of many,” says Malawi’s Vice President and Minister of Natural Resources and Climate Change, Honourable Michael Usi.
Over 550,000 households benefit from this High Quality Gold Standard project which disseminates the “Chitetezo Mbaula” cleaner cook stove, designed, developed and produced in Malawi: tackling 7 Sustainable Development Goals (SDGs). The Stove reduces 46% in-home particles and carbon monoxide by 44%, and decreases firewood consumption by 40%, combating deforestation. By lowering emissions by 2 tCO2e annually per family – Carbon Credits can finance the project.
Final bid credits can be immediately transferred to any GS Registry account or held under escrow by CTX for future resale or cancellation – Voluntary or Nations or CORSIA.
“Finding High Quality ITMOs since we launched the Auction concept at COP28, has been like digging for gold,” says CTX CEO, Wayne Sharpe. “We found the richest vein we could hope for, in our long-standing partners, Gold Standard, and a well-established CTX client. Putting funds into Cookstoves in Malawi ticks every box we ever created CTX for in the first place.”
Gold Standard CEO, Margaret Kim added, “Projects like this one, funded by the purchase of carbon credits, make a real difference to the planet and to people’s health and livelihoods.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20240703957790/en/
Contacts
Wayne Sharpe
auctions@ctxglobal.com
+44 20 3598 5890
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Altasciences Supports 4B Healthcare in Advancing Steroid Nasal Irrigation Rinse to Clinical Trials24.9.2026 15:40:00 EEST | Press release
Altasciences is proud to announce that recent formulation work supporting 4B Healthcare Inc. (“4B”) has helped advance its RhineX nasal irrigation rinse therapy into clinical investigation. Following several months of formulation development, R&D manufacturing, stability testing, and quality assurance support at Altasciences’ CDMO facility in Harleysville, PA, the Tennessee-based pharmaceutical company has received FDA clearance to proceed with clinical testing of RhineX under its IND. First subject dosing is planned for October 2026, approximately seven months after formulation development began. "The concept for RhineX grew out of a problem I have seen in my own ENT practice for years—the need for a better treatment option for allergic rhinitis when conventional medical therapy is not enough,” said Brannon Mangus, MD, Co-Founder and CEO of 4B. “We founded 4B Healthcare to take that physician insight and turn it into a pharmaceutical product that could meaningfully change how these pa
ParaScript Acquired by Stakk to Create a Global Digital Trust Platform Focused on Combating Fraud24.9.2026 15:30:00 EEST | Press release
ParaScript, an Al-powered document processing company, today announced that Stakk Limited (ASX: SKK) (“Stakk”), a company publicly traded on the Australian Stock Exchange (ASX), has successfully completed its US$63 million (A$88.7 million) acquisition of ParaScript, LLC and ParaScript Management, Inc. (“ParaScript”), creating a scaled and profitable AI-native digital trust platform. Stakk acquired ParaScript for its industry-leading AI-powered document processing and recognition technology, which uses advanced machine learning to process large volumes of documents with high speed and accuracy, helping organizations detect fraud earlier, prevent losses and improve outcomes. The combined business becomes one of the largest AI-native digital trust infrastructures serving regulated industries, with more than 300 enterprise customers and more than 110 billion digital interactions processed annually across the U.S., Europe, the Middle East and Australia. Customers include many of the world's
SLB Awarded Four Multi-Year Integrated Well Construction Contracts by Aramco24.9.2026 15:04:00 EEST | Press release
Global energy technology company SLB (NYSE: SLB) today announced it has been awarded four integrated well construction contracts by Aramco to support oil and gas development across the Kingdom of Saudi Arabia. Under the contracts, SLB will manage end-to-end well construction services, delivering more than 450 wells in the three-year term, with an optional extension of up to two years. "Delivering hundreds of wells across a multi-year program and in multiple operating environments requires an integrated model that connects planning, execution, and digital workflows to set new industry performance benchmarks,” said Steve Gassen, executive vice president of Geographies for SLB. “Awarding SLB these advanced well construction programs at scale reflects Aramco’s confidence in our integrated model and capabilities." SLB's integrated well construction model brings together every aspect of well delivery through a technology-enabled operating model. It combines digital drilling workflows with au
Sahajanand Medical Technologies Receives EU MDR Certification for Supraflex Cruz and Product Family, Reinforcing Global Compliance and Patient Safety24.9.2026 15:03:00 EEST | Press release
Sahajanand Medical Technologies Limited (SMT), a leading global manufacturer of cardiovascular medical devices, today announced that it has received certification under the European Union Medical Device Regulation (EU MDR 2017/745) for Supraflex Cruz and its product family. SMT is a leading player in India’s drug-eluting stent market and ranks among the top five companies in key European markets, including Germany, Spain and Poland. The certification follows the conformity assessment process established under EU MDR 2017/745 including assessment of SMT’s technical documentation, clinical evaluation and quality management system. Together with SMT’s existing ISO 13485 quality management system and MDSAP certifications, the EU MDR certification confirms that Supraflex Cruz has successfully undergone assessment against the EU MDR’s stringent requirements for safety, performance and clinical evidence. Supraflex Cruz is a sirolimus-eluting coronary stent system designed to improve luminal d
Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP)24.9.2026 14:00:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced Phase 3 enabling topline results from the Phase 2 portion of the ongoing RADIANT clinical trial program evaluating remlifanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP). For the primary endpoint of change from baseline in the Scale for the Assessment of Positive Symptoms-Hallucinations and Delusions subscales (SAPS-H+D), once daily 60 mg remlifanserin demonstrated a change of -12.6 versus a -10.4 change for placebo at week 6, yielding a standardized effect size of 0.26 (p=0.0603). For the key secondary endpoint, Clinical Global Impression – Severity (CGI-S-ADP), the 60 mg dose achieved a change from baseline of -1.3 versus a change of -0.9 for placebo at week 6, yielding a standardized effect size of 0.37 [p=0.0077 (nominal)]. On both efficacy measures, the difference in the 60 mg dose versus placebo increased through the 6-week treatment period. The 30 mg dose showe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom